1. In Vivo

OMass Therapeutics: The 21st Century Vertex?

 
• By Ayisha Sharma

Hot on the heels of an oversubscribed series B round, OMass CEO and Rising Leader Ros Deegan spoke with In Vivo about her move from pharma to biotech, mass spectrometry and big dreams for the firm.

OMass Was Spun Out Of Oxford University • Source: Alamy

Rising Leaders Home

Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...

More from Rising Leaders

More from Leadership